FIELD: pharmacology; medicine.
SUBSTANCE: invention relates to the field of pharmacology and medicine, namely to the treatment of cognitive functions in a subject. A method for the treatment for improvement of memory and/or cognitive function in a subject who needs such treatment is disclosed, including administration to the subject who needs such treatment of therapeutically effective amount of an antagonist of calcium channels of T type. In this case, the antagonist of calcium channels of T type is MK-8998 or its pharmaceutically acceptable salt. The treatment is used for a condition selected from a group consisting of agnosia, amnesia, Angelman syndrome, Asperger syndrome, autism, cerebral amyloid angiopathy, cognitive disorder caused by alcohol or medications, degenerative dementia, dementia associated with intracranial tumors, Levi’s body disease, multi-infarction dementia, Dravet syndrome, Prader-Willi syndrome, trisomy (including trisomy 21 (Down syndrome)), and Wernicke-Korsakov syndrome.
EFFECT: invention provides effective treatment of memory and/or cognitive function by administration of an antagonist of calcium channels of T type.
MK-8998
7 cl, 1 dwg, 1 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS OF TREATING DRAVET SYNDROME | 2018 |
|
RU2767661C2 |
COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | 2005 |
|
RU2420318C2 |
DPP-IV INHIBITORS FOR TREATMENT OF NEURODEGENERATION AND COGNITIVE DISORDERS | 2005 |
|
RU2394570C2 |
COMPOSITIONS, CONTAINING CHOLINESTERASE INHIBITOR FOR TREATING COGNITIVE DISORDERS | 2010 |
|
RU2607946C2 |
PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING MENTAL, BEHAVIOUR AND COGNITIVE DISORDERS | 2012 |
|
RU2488388C1 |
METHYLTHIONINIUM AS COGNITIVE ENHANCER | 2020 |
|
RU2824584C2 |
3β-(Benzyloxy)-17α-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | 2019 |
|
RU2796005C2 |
THERAPEUTIC APPLICATION OF SELECTIVE INHIBITORS PDE10 | 2003 |
|
RU2303259C2 |
CYCLOPENTYL DERIVATIVES | 2004 |
|
RU2372325C2 |
5-HT RECEPTOR AGONIST COMPOUNDS FOR TREATING COGNITIVE DISORDERS | 2010 |
|
RU2569056C2 |
Authors
Dates
2022-12-05—Published
2018-04-26—Filed